Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Immunomodulatory biopharmaceuticals

Green J, Black, L. Overview of preclinical safety assessment for immunomodulatory biopharmaceuticals. Hum Exp Toxicol 200 19(4) 208-12. [Pg.331]

A number of immunomodulatory biopharmaceuticals (IMBPs), such as peptides, recombinant proteins, soluble receptors, and monoclonal antibodies, have been approved or are currently in development to treat chronic inflammatory diseases. These agents may be administered daily or, if long-acting,... [Pg.601]

IMMUNOMODULATORY BIOPHARMACEUTICALS ARE UNLIKELY TO BE CONVENTIONAL TUMOR PROMOTERS... [Pg.606]

Cavagnaro JA, Spindler P. Methods for predicting tumorigenicity of immunomodulatory biopharmaceuticals. Hum Exp Toxicol 2000 19 213-5. [Pg.624]

See other pages where Immunomodulatory biopharmaceuticals is mentioned: [Pg.89]    [Pg.315]    [Pg.324]    [Pg.399]    [Pg.406]    [Pg.427]    [Pg.492]    [Pg.601]    [Pg.601]    [Pg.601]    [Pg.601]    [Pg.601]    [Pg.602]    [Pg.603]    [Pg.603]    [Pg.604]    [Pg.605]    [Pg.606]    [Pg.607]    [Pg.607]    [Pg.608]    [Pg.609]    [Pg.609]    [Pg.610]    [Pg.612]    [Pg.614]    [Pg.616]    [Pg.618]    [Pg.620]    [Pg.622]    [Pg.624]    [Pg.626]    [Pg.628]    [Pg.630]    [Pg.632]   


SEARCH



Biopharmaceuticals

Biopharmaceutics

Immunomodulatory

Immunomodulatory biopharmaceuticals models

© 2024 chempedia.info